Report Content

Chapter 1   Methodology

1.1    Definition and forecast parameters

1.1.1    Definitions

1.1.2    Methodology and forecast parameters

1.2    Data sources

1.3    References & sources

1.3.1    Secondary

1.3.2    Primary

Chapter 2   Market Summary

2.1    North America self-monitoring blood glucose (SMBG) devices industry summary, 2016 – 2027

2.1.1    Country trends

2.1.2    Product trends

2.1.3    Application trends

2.1.4    Distribution channel trends

Chapter 3   Market Analysis

3.1    Industry segmentation

3.2    Industry outlook, 2016 – 2027 (USD Million)

3.3    Major factor analysis

3.3.1    Drivers

3.3.1.1    Individual and national expenditure over diabetes treatment

3.3.1.2    Technological advancements in self-monitoring glucose devices

3.3.1.3    Increasing adoption of sedentary lifestyle and rising obese population prone to suffer from diabetes

3.3.1.4    Growing prevalence of diabetes

3.3.2    Industry pitfalls & challenges

3.3.2.1    High cost associated with SMBG devices

3.4    Analysis of COVID-19 impact on the industry

3.5    Porter’s analysis

3.6    Competitive review, 2020

3.7    PEST analysis

Chapter 4   North America Self-monitoring Blood Glucose (SMBG) Devices Market, By Product

4.1    Market trends

4.2    Self-monitoring blood glucose meters

4.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.3    Continuous glucose monitors

4.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.4    Testing strips

4.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.5    Lancets

4.5.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 5   North America Self-monitoring Blood Glucose (SMBG) Devices Market, By Application

5.1    Market trends

5.2    Type 1 diabetes

5.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.3    Type 2 diabetes

5.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.4    Gestational diabetes

5.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 6   North America Self-monitoring Blood Glucose (SMBG) Devices Market, By Distribution Channel

6.1    Market trends

6.2    Hospital pharmacies

6.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

6.3    Retail pharmacies

6.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

6.4    Online sales

6.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

6.5    Diabetes Clinics & Centers

6.5.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 7   North America Self-monitoring Blood Glucose (SMBG) Devices Market, By Country

7.1    Market trends

7.2    U.S.

7.2.1    Market estimates and forecast, by product, 2016 – 2027 (USD Million)

7.2.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

7.2.3    Market estimates and forecast, by distribution channel, 2016 – 2027 (USD Million)

7.3    Canada

7.3.1    Market estimates and forecast, by product, 2016 – 2027 (USD Million)

7.3.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

7.3.3    Market estimates and forecast, by distribution channel, 2016 – 2027 (USD Million)

Chapter 8   Company Profiles

8.1    Abbott Laboratories

8.1.1    Business overview

8.1.2    Financial data

8.1.3    Product landscape

8.1.4    Strategic outlook

8.1.5    SWOT analysis

8.2    Arkray

8.2.1    Business overview

8.2.2    Financial data

8.2.3    Product landscape

8.2.4    Strategic outlook

8.2.5    SWOT analysis

8.3    B. Braun Melsungen AG

8.3.1    Business overview

8.3.2    Financial data

8.3.3    Product landscape

8.3.4    Strategic outlook

8.3.5    SWOT analysis

8.4    Bayer Healthcare

8.4.1    Business overview

8.4.2    Financial data

8.4.3    Product landscape

8.4.4    Strategic outlook

8.4.5    SWOT analysis

8.5    Bionime Corporation.

8.5.1    Business overview

8.5.2    Financial data

8.5.3    Product landscape

8.5.4    Strategic outlook

8.5.5    SWOT analysis

8.6    F. Hoffmann-La Roche AG

8.6.1    Business overview

8.6.2    Financial data

8.6.3    Product landscape

8.6.4    Strategic outlook

8.6.5    SWOT analysis

8.7    Platinum Equity (LifeScan)

8.7.1    Business overview

8.7.2    Financial data

8.7.3    Product landscape

8.7.4    Strategic outlook

8.7.5    SWOT analysis

8.8    Agamatrix Inc

8.8.1    Business overview

8.8.2    Financial data

8.8.3    Product landscape

8.8.4    Strategic outlook

8.8.5    SWOT analysis

8.9    Dexcom

8.9.1    Business overview

8.9.2    Financial data

8.9.3    Product landscape

8.9.4    Strategic outlook

8.9.5    SWOT analysis

8.10    Johnson & Johnson

8.10.1    Business overview

8.10.2    Financial data

8.10.3    Product landscape

8.10.4    Strategic outlook

8.10.5    SWOT analysis

8.11    Medtronic

8.11.1    Business overview

8.11.2    Financial data

8.11.3    Product landscape

8.11.4    Strategic outlook

8.11.5    SWOT analysis

8.12    Nipro Diagnostics

8.12.1    Business overview

8.12.2    Financial data

8.12.3    Product landscape

8.12.4    Strategic outlook

8.12.5    SWOT analysis

8.13    Nova Biomedical

8.13.1    Business overview

8.13.2    Financial data

8.13.3    Product landscape

8.13.4    Strategic outlook

8.13.5    SWOT analysis

8.14    Trividia Health

8.14.1    Business overview

8.14.2    Financial data

8.14.3    Product landscape

8.14.4    Strategic outlook

8.14.5    SWOT analysis

8.15    Sinocare

8.15.1    Business overview

8.15.2    Financial data

8.15.3    Product landscape

8.15.4    Strategic outlook

8.15.5    SWOT analysis